1. Gilead says remdesivir cut risk of COVID patient death in clinical trial — BioNTech-Pfizer COVID vaccine expected to be ready for approval by year end — LEO Pharma eyeing 2021 launch for Dupixent rival — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

FDA tells Eli Lilly it can quickly refile NDA for hopeful Baricitinib

Discussion in 'Eli Lilly' started by RobertPhillips900, Aug 30, 2017 at 10:09 AM.

  1. RobertPhillips900

    Aug 29, 2016
    Likes Received:
    Lilly will resubmit the New Drug Application for rheumatoid arthritis medication baricitinib, to the U.S. Food and Drug Administration (FDA), before the end of January 2018. The companies anticipate the FDA will classify the application as a Class II resubmission, which will start a new six-month review cycle. http://alph.st/b283c853